Abeer Siddiqi, MD
Hospitalist · Houston, TXNPI 1588059539
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,078 of the $8,631 with a category attached, or 82.0%. 23 manufacturers reported payments, led by Sanofi at 35.2% of the total. 2025 is the largest year on record at $3,816, 9.2 times the $416 reported in 2021. Among hospitalist clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 248 payments — averaging $34.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$3K
- AstraZeneca$1K
- GSK$801
- Regeneron Healthcare Solutions, Inc.$592
- Alk-abello, Inc$542
- Takeda Pharmaceuticals U.S.A., Inc.$362
- plus $2K from 17 others
What the payments were for
- Consulting fees$1,44617%
- Travel & lodging$721%
- Food & beverage$7,07882%
- Education$340%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 36 | $3,034 |
| AstraZeneca | 41 | $1,314 |
| GSK | 22 | $801 |
| Regeneron Healthcare Solutions, Inc. | 31 | $592 |
| Alk-abello, Inc | 13 | $542 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $362 |
| Inspire Medical Systems, Inc. | 17 | $317 |
| Optinose US, Inc. | 11 | $310 |
| Genentech USA, Inc. | 14 | $216 |
| ARS Pharmaceuticals Operations, Inc. | 8 | $209 |
| Blueprint Medicines Corporation | 4 | $188 |
| Kaleo, Inc. | 6 | $141 |
| Novartis | 6 | $111 |
| CSL Behring | 4 | $82 |
| Amgen | 3 | $75 |
| Organon | 3 | $64 |
| Galderma Laboratories, L.p. | 3 | $55 |
| Pfizer | 3 | $54 |
| Hikma Pharmaceuticals USA | 2 | $42 |
| Medtronic | 2 | $40 |
| Grifols USA, LLC | 2 | $39 |
| Phadia US Inc. | 1 | $24 |
| LEO Pharma Inc. | 1 | $19 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,631 in reported general payments places this provider in the 95th percentile of 1,284 hospitalist providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TezspireTezepelumab-Ekko | 14 | $61,207 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 12 | $13,874 |
| Epinephrine | 59 | $8,964 |
| SymbicortBudesonide/Formoterol Fumarate | 14 | $3,777 |
| Azelastine Hcl | 61 | $1,767 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 32 | $701 |
| Montelukast Sodium | 73 | $488 |
| Fluticasone Propionate | 28 | $378 |
| Levocetirizine Dihydrochloride | 40 | $287 |
| Famotidine | 14 | $278 |
| Ipratropium Bromide | 12 | $223 |
| Triamcinolone Acetonide | 11 | $111 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $104 |
| Prednisone | 35 | $51 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaTezspire, Symbicort | $1,314 | $64,98428 claims |
| GSKTrelegy Ellipta | $801 | $13,87412 claims |
| Hikma Pharmaceuticals USAEpinephrine | $42 | $8,96459 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,284 hospitalist providers in Texas.
Other hospitalist in Houston
- Ryan NealHouston$154K
- Ahmad BaroutHouston$44K
- Laxman KalvakuntlaHouston$30K
- Joshua HahnHouston$23K
- Grace OdiHouston$14K
- Spencer SuHouston$9K
- Martin Chacon PortilloHouston$9K
- Brent GudenkaufHouston$8K
- Dilpreet SinghHouston$7K
- John FlynnHouston$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.